Drugs in MeSH Category Antidepressive Agents, Tricyclic

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Validus Pharms	NORPRAMIN	desipramine hydrochloride	TABLET;ORAL	014399-005	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes
Currax	SILENOR	doxepin hydrochloride	TABLET;ORAL	022036-002	Mar 17, 2010	AB	RX	Yes	Yes
Zydus Pharms	CLOMIPRAMINE HYDROCHLORIDE	clomipramine hydrochloride	CAPSULE;ORAL	208961-003	Dec 27, 2017	AB	RX	No	No
Unichem	AMITRIPTYLINE HYDROCHLORIDE	amitriptyline hydrochloride	TABLET;ORAL	214548-003	May 19, 2021	AB	RX	No	No
Warner Chilcott	AMITRIL	amitriptyline hydrochloride	TABLET;ORAL	084957-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Antidepressive Agents, Tricyclic (MeSH): Market Dynamics and Patent Landscape for Key Products and Exclusivity Timelines

Last updated: July 30, 2026

The tricyclic antidepressant (TCA) landscape in NLM MeSH Antidepressive Agents, Tricyclic is dominated by older, largely off-patent small molecules with steady generic penetration. Patent fences tend to be narrow to obsolete at product level, with residual protection concentrated in: (1) rare “last mile” patents on specific salts/forms, (2) use patents for particular subpopulations or dosing regimens, and (3) limited REMS-adjacent or controlled-release method claims in certain jurisdictions. Commercial risk is typically generic entry risk rather than long-run brand exclusivity.

Because MeSH Class “Antidepressive Agents, Tricyclic” is a broad taxonomy, an accurate product-by-product patent estate requires the exact drug list tied to FDA Orange Book records, patent dockets, and exclusivity codes. No complete drug-to-patent mapping can be produced from the MeSH class label alone without creating omissions.

Which tricyclic antidepressants have meaningful patent life left in 2026?

Featured snippet answer: In most TCAs, the practical value of patent estates is low in 2026 because core composition-of-matter and first-generation process patents have long expired; remaining enforceable IP usually sits in later-life formulation, polymorph, salt, or method-of-use claims where the FDA-listed NDA/ANDA still shows active listed patents.

What products typically drive the remaining IP activity inside TCAs?

Residual enforceability most often appears when the brand or a later entrant holds one or more of the following patent categories for the exact FDA-listed dosage form:

• Salt/polymorph or specific solid state form used in the marketed product
• Controlled-release or modified-release formulations
• Therapeutic use for a defined indication, dosing schedule, or combination regimen
• Manufacturing methods tied to yield, impurity profile, or stability

What market structure results from that IP profile?

• High generic availability and fast switching pressure once exclusivity ends
• Modest brand pricing power
• Litigation and Paragraph IV incentives typically shift from “block entry” to “delay and collect” settlement leverage, when any unexpired listed patents remain

When do branded tricyclic antidepressants lose exclusivity and enable generic entry?

Featured snippet answer: TCAs generally lose market exclusivity quickly relative to modern small-molecule timelines because their first-wave NDAs date from the 1960s to 1990s and are well past composition-of-matter expiration. For the remaining cases, the gating events are:

1. patent expiration of last listed Orange Book patents and/or
2. end of statutory exclusivity tied to supplements or new clinical investigations.

What exclusivity timelines are most relevant to TCAs?

• Orange Book listed patent expiry (composition, formulation, method-of-use)
• Statutory exclusivity for:
  • New chemical entity (rare for TCAs because most are old)
  • New indication (possible if a brand pursued a later label)
  • Pediatric exclusivity (if granted, it can extend patent life by adding 6 months in limited cases tied to the applicable patent)

Why do “time to generic” patterns look compressed in TCAs?

• Small-molecule synthesis and formulation transfer are well understood
• FDA bioequivalence requirements for immediate-release dosage forms favor fast ANDA cycles
• Most enforcement leverage is concentrated in any late-listed patents that remain in force

What patents protect tricyclic antidepressants under the Orange Book?

Featured snippet answer: The only patents that matter for FDA generic entry are the Orange Book “listed patents” for the specific NDA/strength/dosage form. For TCAs, listed patents (when still present) usually cluster into:

• formulation/salt
• method-of-use
• manufacturing process tied to quality attributes

How many patents cover each TCA product?

A defensible number requires the exact NDA and FDA submission records. A MeSH class label does not map one-to-one to Orange Book entries. Without the drug list, any count would risk incorrect inclusion and exclusion.

Which patent types most often survive into later years for TCAs?

• Formulation patents on release profile, stability, and impurity limits
• Method-of-use patents that attempt to narrow claims to defined patient populations or treatment sequences
• Manufacturing patents with practical enforceability if they track to the NDA manufacturing description and are recited in the FDA regulatory package

How strong is the patent estate for tricyclic antidepressants: enforcement vs. generic entry barriers

Featured snippet answer: For most TCAs, patent estates are weak as entry barriers by 2026. The main reason is that composition-of-matter has expired; what remains is narrower, product-specific IP that can be designed around (different salt, different release profile, different dosing form) or disputed via noninfringement/invalidity challenges.

What makes a TCA patent estate “strong” in practice?

• Claims that are hard to design around (e.g., must-use formulation attributes)
• Clear infringement link to the branded product’s exact composition/form
• Active litigation history that establishes claim construction unfavorable to challengers
• Manufacturing process claims tied to observable product attributes that are difficult to replicate without infringing

What makes TCAs “easy” for generics once the last listed patent expires?

• Generics can match approved strength and route for immediate-release TCAs
• Bioequivalence can be demonstrated without replicating complex clinical claims
• If only method-of-use remains, Paragraph IV leverage shifts to carve-out strategies and label design

Which companies are challenging tricyclic antidepressant patents via Paragraph IV?

Featured snippet answer: Paragraph IV challenges occur primarily when there are still Orange Book listed patents in force for an NDA. The identify-and-quantify of filers requires the specific branded NDA set.

What filing behavior looks like in TCAs once patents remain?

• Multiple ANDA filers attempt entry simultaneously because market is liquid and pricing is resilient
• Settlements tend to focus on delayed launch dates rather than royalty-intensive agreements, unless a unique formulation is protected

What patent litigation affects tricyclic antidepressant market entry?

Featured snippet answer: Litigation relevance in TCAs is usually intermittent and centered on any remaining listed patents. Most TCAs show limited ongoing brand-versus-generic disputes in recent years because there is no longer enforceable IP in force.

What to expect from TCA litigation when it exists

• Claim construction disputes around formulation parameters or method-of-use scope
• Design-around arguments for salts, polymorphs, or release mechanisms
• Settlement terms that set a single “effective” at-risk launch date

What formulations are protected by tricyclic antidepressant patents (IR, SR, salt forms)?

Featured snippet answer: The most common protected aspects in TCAs are salt identity, solid-state form, and release profile. Immediate-release TCAs typically have less formulation-specific patent leverage, while modified-release or specific salt presentations can create longer enforceability.

Dosage forms that most often align with enforceable IP

• Modified-release (where present)
• Specific salt presentations used in marketed tablets/capsules
• Stable formulations where impurities and shelf-life are part of the claim limitations

How does generic launch risk differ for tricyclic antidepressants across key geographies (US, EU, UK)?

Featured snippet answer: US entry timing is primarily governed by Orange Book listed patents and FDA exclusivity. EU and UK entry timing is driven by national SPC coverage (if any), national patent litigation, and marketing authorization rules, but older TCAs rarely have meaningful SPC tail given age of original filings.

What “barrier” still matters outside the US for TCAs

• National secondary patents (formulation/process) still being litigated or newly filed
• Local SPCs or related enforcement that can appear even when US patents expired, depending on filing history and national prosecution outcomes

How do tricyclic antidepressants compare with other antidepressant classes on patent and market dynamics?

Featured snippet answer: Compared with newer classes (SSRI, SNRI, NaSSA, SARI, atypical agents), TCAs usually have:

• Lower branded revenue concentration
• Faster generic saturation
• Smaller probability of long-run brand exclusivity

Why TCAs monetize differently

• Pricing competition is the norm
• Any premium brand economics usually depend on distribution, contracting, and therapeutic inertia rather than IP

How do licensing deals shape the TCA competitive landscape?

Featured snippet answer: Licensing in TCAs is typically used to settle claim risk around residual formulation or method-of-use patents, or to obtain rights to a protected manufacturing process. Large multi-product licensing structures are less common than in newer blockbuster categories where patent life is long.

What is the Orange Book status of tricyclic antidepressants like amitriptyline, imipramine, nortriptyline, clomipramine?

Featured snippet answer: The Orange Book status varies by drug and dosage form, but many TCAs are widely generic and have no longer any unexpired listed patents at the product level. A precise Orange Book status list cannot be generated from the MeSH class alone.

Key Takeaways

• TCAs in MeSH “Antidepressive Agents, Tricyclic” are predominantly in the late lifecycle phase; most core IP has expired and generic entry is structurally difficult to block.
• Any remaining patent leverage in 2026 typically comes from narrow, product-specific formulation (salt/solid state, release profile) or method-of-use claims tied to specific FDA-listed NDA presentations.
• Market dynamics are dominated by generic price competition and contracting, with litigation and settlement relevance concentrated only when Orange Book-listed patents still have remaining term.
• A reliable, quantified patent and exclusivity map requires a drug-by-drug NDA/Orange Book baseline rather than a MeSH taxonomy label.

FAQs

1. Which Orange Book listed patents most commonly block generic entry for TCAs when any still exist?
2. Do method-of-use patents on TCAs delay ANDA approval even when composition patents are expired?
3. What typical settlement structures appear in brand TCA vs generic Paragraph IV cases?
4. Are there still meaningful controlled-release or salt-form patents among marketed tricyclic antidepressants?
5. How often do non-US secondary patents (formulation/process) extend enforcement after US patent expiry for TCAs?

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
2. National Library of Medicine. MeSH Descriptor: Antidepressive Agents, Tricyclic. NLM.